118 related articles for article (PubMed ID: 37783391)
21. LSD1-Demethylated LINC01134 Confers Oxaliplatin Resistance Through SP1-Induced p62 Transcription in HCC.
Ma L; Xu A; Kang L; Cong R; Fan Z; Zhu X; Huo N; Liu W; Xue C; Ji Q; Li W; Chu Z; Kang X; Wang Y; Sun Z; Han Y; Liu H; Gao X; Han J; You H; Zhao C; Xu X
Hepatology; 2021 Dec; 74(6):3213-3234. PubMed ID: 34322883
[TBL] [Abstract][Full Text] [Related]
22. LncRNA AC026401.3 interacts with OCT1 to intensify sorafenib and lenvatinib resistance by activating E2F2 signaling in hepatocellular carcinoma.
Wang Y; Tan K; Hu W; Hou Y; Yang G
Exp Cell Res; 2022 Nov; 420(1):113335. PubMed ID: 36084669
[TBL] [Abstract][Full Text] [Related]
23. Suppression of DRP1‑mediated mitophagy increases the apoptosis of hepatocellular carcinoma cells in the setting of chemotherapy.
Ma M; Lin XH; Liu HH; Zhang R; Chen RX
Oncol Rep; 2020 Mar; 43(3):1010-1018. PubMed ID: 32020220
[TBL] [Abstract][Full Text] [Related]
24. Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma.
Pan J; Zhang M; Dong L; Ji S; Zhang J; Zhang S; Lin Y; Wang X; Ding Z; Qiu S; Gao D; Zhou J; Fan J; Gao Q
Autophagy; 2023 Apr; 19(4):1184-1198. PubMed ID: 36037300
[TBL] [Abstract][Full Text] [Related]
25. EGFR activation limits the response of liver cancer to lenvatinib.
Jin H; Shi Y; Lv Y; Yuan S; Ramirez CFA; Lieftink C; Wang L; Wang S; Wang C; Dias MH; Jochems F; Yang Y; Bosma A; Hijmans EM; de Groot MHP; Vegna S; Cui D; Zhou Y; Ling J; Wang H; Guo Y; Zheng X; Isima N; Wu H; Sun C; Beijersbergen RL; Akkari L; Zhou W; Zhai B; Qin W; Bernards R
Nature; 2021 Jul; 595(7869):730-734. PubMed ID: 34290403
[TBL] [Abstract][Full Text] [Related]
26. Lenvatinib Synergistically Promotes Radiation Therapy in Hepatocellular Carcinoma by Inhibiting Src/STAT3/NF-κB-Mediated Epithelial-Mesenchymal Transition and Metastasis.
Weng YS; Chiang IT; Tsai JJ; Liu YC; Hsu FT
Int J Radiat Oncol Biol Phys; 2023 Mar; 115(3):719-732. PubMed ID: 36245124
[TBL] [Abstract][Full Text] [Related]
27. KDM6A promotes hepatocellular carcinoma progression and dictates lenvatinib efficacy by upregulating FGFR4 expression.
Guo W; Li S; Qian Y; Li L; Wang F; Tong Y; Li Q; Zhu Z; Gao WQ; Liu Y
Clin Transl Med; 2023 Oct; 13(10):e1452. PubMed ID: 37846441
[TBL] [Abstract][Full Text] [Related]
28. Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation.
Fernández-Palanca P; Payo-Serafín T; San-Miguel B; Méndez-Blanco C; Tuñón MJ; González-Gallego J; Mauriz JL
Acta Pharmacol Sin; 2023 May; 44(5):1066-1082. PubMed ID: 36376373
[TBL] [Abstract][Full Text] [Related]
29. circKCNN2 suppresses the recurrence of hepatocellular carcinoma at least partially via regulating miR-520c-3p/methyl-DNA-binding domain protein 2 axis.
Liu D; Liu W; Chen X; Yin J; Ma L; Liu M; Zhou X; Xian L; Li P; Tan X; Zhao J; Liao Y; Cao G
Clin Transl Med; 2022 Jan; 12(1):e662. PubMed ID: 35051313
[TBL] [Abstract][Full Text] [Related]
30. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
Kimura T; Kato Y; Ozawa Y; Kodama K; Ito J; Ichikawa K; Yamada K; Hori Y; Tabata K; Takase K; Matsui J; Funahashi Y; Nomoto K
Cancer Sci; 2018 Dec; 109(12):3993-4002. PubMed ID: 30447042
[TBL] [Abstract][Full Text] [Related]
31. Broad-spectrum kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinoma.
Leung CON; Yang Y; Leung RWH; So KKH; Guo HJ; Lei MML; Muliawan GK; Gao Y; Yu QQ; Yun JP; Ma S; Zhao Q; Lee TKW
Nat Commun; 2023 Oct; 14(1):6699. PubMed ID: 37872167
[TBL] [Abstract][Full Text] [Related]
32. CRISPR/Cas9 genome-wide screening identifies KEAP1 as a sorafenib, lenvatinib, and regorafenib sensitivity gene in hepatocellular carcinoma.
Zheng A; Chevalier N; Calderoni M; Dubuis G; Dormond O; Ziros PG; Sykiotis GP; Widmann C
Oncotarget; 2019 Dec; 10(66):7058-7070. PubMed ID: 31903165
[TBL] [Abstract][Full Text] [Related]
33. Mitochondrial ROS driven by NOX4 upregulation promotes hepatocellular carcinoma cell survival after incomplete radiofrequency ablation by inducing of mitophagy via Nrf2/PINK1.
Peng C; Li X; Ao F; Li T; Guo J; Liu J; Zhang X; Gu J; Mao J; Zhou B
J Transl Med; 2023 Mar; 21(1):218. PubMed ID: 36964576
[TBL] [Abstract][Full Text] [Related]
34. Cepharanthine hydrochloride induces mitophagy targeting GPR30 in hepatocellular carcinoma (HCC).
Wang Y; Su GF; Huang ZX; Wang ZG; Zhou PJ; Fan JL; Wang YF
Expert Opin Ther Targets; 2020 Apr; 24(4):389-402. PubMed ID: 32106726
[No Abstract] [Full Text] [Related]
35. Revealing the suppressive role of protein kinase C delta and p38 mitogen-activated protein kinase (MAPK)/NF-κB axis associates with lenvatinib-inhibited progression in hepatocellular carcinoma in vitro and in vivo.
Wu CH; Hsu FT; Chao TL; Lee YH; Kuo YC
Biomed Pharmacother; 2022 Jan; 145():112437. PubMed ID: 34864311
[TBL] [Abstract][Full Text] [Related]
36. EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells.
He X; Hikiba Y; Suzuki Y; Nakamori Y; Kanemaru Y; Sugimori M; Sato T; Nozaki A; Chuma M; Maeda S
Sci Rep; 2022 May; 12(1):8007. PubMed ID: 35568782
[TBL] [Abstract][Full Text] [Related]
37. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
Yi C; Chen L; Lin Z; Liu L; Shao W; Zhang R; Lin J; Zhang J; Zhu W; Jia H; Qin L; Lu L; Chen J
Hepatology; 2021 Nov; 74(5):2544-2560. PubMed ID: 34036623
[TBL] [Abstract][Full Text] [Related]
38. Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cells.
Ao J; Chiba T; Shibata S; Kurosugi A; Qiang N; Ma Y; Kan M; Iwanaga T; Sakuma T; Kanzaki H; Kanayama K; Kojima R; Kusakabe Y; Nakamura M; Saito T; Nakagawa R; Kondo T; Ogasawara S; Suzuki E; Muroyama R; Kato J; Mimura N; Kanda T; Maruyama H; Kato N
Biochem Biophys Res Commun; 2021 Apr; 549():171-178. PubMed ID: 33676186
[TBL] [Abstract][Full Text] [Related]
39. Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC.
Wei L; Lee D; Law CT; Zhang MS; Shen J; Chin DW; Zhang A; Tsang FH; Wong CL; Ng IO; Wong CC; Wong CM
Nat Commun; 2019 Oct; 10(1):4681. PubMed ID: 31615983
[TBL] [Abstract][Full Text] [Related]
40. Sanguinarine impairs lysosomal function and induces ROS-dependent mitophagy and apoptosis in human hepatocellular carcinoma cells.
Wang J; Su Q; Wu Q; Chen K; Ullah A; Ghauri MA; Zhang Y
Arch Pharm Res; 2021 Nov; 44(11):1025-1036. PubMed ID: 34751932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
